On June 24, Lundbeck Korea announced that they will launch new treatment for Parkinson's disease 'Azilect' in Korea

Published: 2014-06-26 15:25:43

Updated: 2014-06-26 15:25:43

On June 24, Lundbeck Korea announced that they will launch new treatment for Parkinson's disease 'Azilect' in Korea on July 1 after a 10-year hiatus.

'Azilect' (ingredients: Rasagilin mesylate) is a second-generation selective irreversible MAO-B (monoamine oxidase type B) inhibitor, which acts as the Parkinson's disease treatment.

Azilect is recommended as A level drug on the guildline of Eur...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.